Dianthus Therapeutics (DNTH) Operating Income (2017 - 2025)

Dianthus Therapeutics' Operating Income history runs 9 years deep, the most recent figure standing at -$40.3 million for Q3 2025.

• In Q3 2025, Operating Income fell 34.74% year-over-year to -$40.3 million; the TTM figure through Sep 2025 stood at -$140.3 million (down 69.24% YoY), while the FY2024 annual figure was -$101.9 million, down 111.45% from the prior year.
• Operating Income for Q3 2025 stood at -$40.3 million, down from -$34.9 million in the prior quarter.
• The five-year high for Operating Income was -$7.7 million in Q1 2023, with the low at -$40.3 million in Q3 2025.
• The 5-year median for Operating Income is -$18.2 million (2021), against an average of -$20.7 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income soared 67.76% in 2023, then plunged 146.34% in 2024.
• Dianthus Therapeutics' Operating Income stood at -$20.1 million in 2021, then surged by 46.91% to -$10.7 million in 2022, then fell by 21.16% to -$13.0 million in 2023, then slumped by 146.34% to -$31.9 million in 2024, then slipped by 26.23% to -$40.3 million in 2025.
• Business Quant data shows DNTH's Operating Income at -$40.3 million in Q3 2025, -$34.9 million in Q2 2025, and -$33.2 million in Q1 2025.